Unlock AI-driven, actionable R&D insights for your next breakthrough.

Creatine Phosphate Handling: Comprehensive Analysis Of Synthesis, Stability, Delivery Systems, And Therapeutic Applications

NOV 17, 202668 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Creatine Phosphate Handling encompasses the critical processes of synthesis, stabilization, formulation, and delivery of creatine phosphate (phosphocreatine) for both research and therapeutic applications. As a high-energy phosphate compound central to cellular energy metabolism, creatine phosphate serves as a rapid ATP regeneration system in tissues with fluctuating energy demands, including skeletal muscle, cardiac tissue, and neural cells. Effective handling protocols are essential to preserve the chemical integrity of this labile molecule while optimizing bioavailability and therapeutic efficacy across diverse clinical contexts ranging from cardiovascular disorders to neurodegenerative diseases.
Want to know more material grades? Try Patsnap Eureka Material.

Molecular Structure And Chemical Stability Characteristics Of Creatine Phosphate

Creatine phosphate (CrP), also known as phosphocreatine, represents a phosphorylated derivative of creatine bearing a high-energy N-phosphoryl bond. The molecular formula is C₄H₁₀N₃O₅P with a molecular weight of approximately 211.11 g/mol 1. This compound exists as a zwitterion under physiological pH, contributing to its solubility profile and membrane permeability characteristics 12,15.

The chemical stability of creatine phosphate presents significant handling challenges. Historically, CrP was considered extremely temperature-sensitive and prone to rapid hydrolysis under acidic conditions 1. However, systematic investigation has revealed that creatine phosphate can withstand heating at 80–90°C for up to 10 minutes in weakly alkaline environments (pH 7.5–8.5) without perceptible degradation 1. This thermal tolerance window is critical for enzymatic synthesis termination and purification protocols.

Key Stability Parameters:

  • pH Sensitivity: CrP undergoes rapid hydrolysis below pH 6.0, with half-life dropping to minutes at pH 4.0 1. Optimal stability occurs at pH 7.0–9.0 where the compound remains intact for extended periods at refrigerated temperatures (2–8°C).
  • Temperature Dependence: At room temperature (20–25°C) in neutral aqueous solution, CrP exhibits a half-life of approximately 24–48 hours 1. Freezing at −20°C or below extends stability to several months when stored in appropriate buffer systems.
  • Ionic Strength Effects: The presence of divalent cations, particularly Mg²⁺ and Ca²⁺, can influence CrP stability through coordination interactions, though concentrations above 10 mM may promote precipitation of phosphate salts 1.

The acid-sensitivity of phosphocreatine precludes conventional isolation methods used for nucleotides or sugar phosphates, such as ion-exchange chromatography or activated charcoal adsorption, as even brief acidification results in substantial losses 1. Modern handling protocols therefore emphasize maintenance of alkaline conditions throughout synthesis, purification, and storage phases.

Enzymatic Synthesis Routes For Creatine Phosphate Production

The enzymatic preparation of creatine phosphate offers significant advantages over chemical synthesis in terms of stereochemical purity, reaction selectivity, and environmental sustainability. The primary enzymatic route involves the creatine phosphokinase (CPK, also termed creatine kinase) catalyzed transfer of phosphate from a donor substrate to creatine 1,6.

Classical Synthesis Using 3-Phosphoglyceric Acid

A well-established method employs 3-phosphoglyceric acid as the phosphate donor in the presence of aqueous muscle extract containing endogenous creatine phosphokinase 1. The reaction proceeds optimally under the following conditions:

  • Substrate Ratio: Approximately 1.1–1.5 molar equivalents of creatine per equivalent of 3-phosphoglyceric acid to ensure complete conversion of the phosphate donor 1
  • pH Range: Weakly alkaline medium (pH 7.8–8.5) maintained without formal buffer addition, relying on the natural buffering capacity of muscle extract 1
  • Enzyme Source: Crude muscle extract from rabbit or veal tissue, filtered to remove insoluble components, providing sufficient CPK activity (1 unit per 1–10 mg creatine) 1
  • Cofactor Requirements: Catalytic amounts of ATP (0.1–1.0 mM), with Mg²⁺ and K⁺ ions at concentrations of 1–2 × 10⁻³ M to support enzyme activity 1
  • Reaction Termination: Heating to 70–100°C for a brief period (typically 5–10 minutes at 80–90°C) to denature enzymes while preserving CrP integrity 1

This approach achieves near-quantitative conversion and simplifies downstream purification by thermal inactivation of enzymatic components. The surprising thermal stability of CrP in alkaline conditions enables this heat-treatment step, which was previously considered incompatible with phosphocreatine handling 1.

Alternative Phosphate Donors And ATP Regeneration Systems

While 3-phosphoglyceric acid serves as an effective phosphate donor, alternative systems have been explored to optimize cost-efficiency and reaction kinetics. Direct phosphorylation using ATP as the phosphate donor, coupled with ATP regeneration systems employing creatine phosphate itself, creates a paradoxical but functional cycle when initiated with catalytic ATP quantities 5,16.

In cell-free protein synthesis (CFPS) systems, creatine phosphate functions as a secondary energy source, donating phosphate to ADP for ATP regeneration 16. However, this leads to phosphate accumulation as a reaction byproduct, necessitating periodic adjustment of energy charge through addition of phosphate-free energy sources such as glucose or dextran combined with exogenous phosphate sources (potassium phosphate, magnesium phosphate) and cyclic AMP (0.05–5.0 mM) 16.

Formulation Strategies For Enhanced Bioavailability And Cellular Uptake

The therapeutic utility of creatine phosphate is fundamentally limited by its poor membrane permeability due to the charged phosphate moiety. Multiple formulation strategies have been developed to overcome this barrier and enhance intracellular delivery.

Membrane-Permeable Prodrug Approaches

A sophisticated approach involves synthesis of membrane-permeable prodrugs wherein the phosphate group is masked through esterification or other reversible modifications 2,3,4. These prodrugs are designed to:

  • Traverse cellular membranes via passive diffusion or transporter-mediated uptake
  • Undergo intracellular enzymatic or chemical cleavage to release active creatine phosphate
  • Minimize premature hydrolysis in the gastrointestinal tract or bloodstream

Patent literature describes compounds of Formula (I), (II), and (III) incorporating salicyl alcohol moieties, cyclic structures, and other lipophilic groups that enhance membrane permeability while maintaining the capacity for intracellular phosphate release 2,3,4. These prodrugs have demonstrated efficacy in treating ischemia, heart failure, and neurodegenerative disorders in preclinical models 2,3,4.

Controlled-Release Delivery Systems

Controlled-release formulations address the rapid clearance and urinary excretion of creatine and creatine phosphate following oral administration 17. Conventional creatine supplementation produces sharp plasma concentration spikes followed by rapid decline, with substantial urinary losses 17.

Design Principles For Controlled Delivery:

  • Encapsulation Technologies: Incorporation of creatine or CrP into polymer matrices, liposomes, or other encapsulation vehicles that provide gradual release over 4–8 hours 17
  • Target Release Rate: Controlled delivery systems aim to provide 0.2–1.5 g creatine per hour, maintaining elevated plasma levels for extended periods 17
  • Tissue Retention Enhancement: By avoiding supraphysiological plasma peaks, controlled-release formulations increase the proportion of administered creatine retained in muscle and other tissues, potentially reducing total dose requirements by 30–50% compared to conventional loading protocols 17

Combination Formulations With Transport Enhancers

Nutritional compositions combining creatine phosphate with compounds that enhance cellular uptake represent another strategic approach 5,7,8,9. Key components include:

  • Taurine: An amino acid that may facilitate creatine transporter activity and cell volumization 5
  • Phosphate Sources: Supplemental phosphate salts (0.1–1.5 g per serving) to support 2,3-DPG synthesis in erythrocytes, enhancing oxygen delivery to tissues and potentially increasing VO₂ max 5
  • Alpha-Lipoic Acid: A mitochondrial cofactor that may enhance insulin-mediated glucose and creatine uptake into muscle cells 5
  • Carbohydrate Co-Administration: Dextrose, isomalt, trehalose, or D-mannose to stimulate insulin release and activate creatine transporters 5

Creatinol-O-phosphate, a hydroxylated analog, has been incorporated into timed-release formulations (0.5–5 g per serving, preferably 1.5 g twice daily) for its purported role in ATP synthesis enhancement and hydrogen ion buffering during intense muscular exercise 7,8,9.

Analytical Methods For Creatine Phosphate Quantification And Quality Control

Accurate quantification of creatine phosphate in biological samples, pharmaceutical formulations, and research preparations requires specialized analytical techniques that account for the compound's lability and the presence of interfering substances.

Bioluminescence-Based Assays

The most sensitive method for CrP determination exploits the creatine kinase reaction coupled to luciferase-based ATP detection 14. The assay protocol involves:

  1. ATP Elimination: Initial treatment with AMP (125 mM) to decompose endogenous ATP in blood or tissue samples, reducing background signal 14
  2. Adenylate Kinase Inhibition: Addition of diadenosine pentaphosphate (DAPP, 0.2 μM) to prevent AMP-mediated ATP regeneration via adenylate kinase 14
  3. CrP-to-ATP Conversion: Introduction of ADP (20 μM) and creatine phosphate standards or samples, allowing creatine kinase to catalyze ATP formation 14
  4. Bioluminescent Detection: Addition of luciferin-luciferase reagent, with light emission quantified by luminometry 14

This method achieves picomolar sensitivity and shows excellent correlation (r > 0.95) with spectrophotometric reference methods while requiring minimal sample volume 14.

Spectrophotometric Enzyme-Coupled Assays

Traditional spectrophotometric methods monitor NADH oxidation or formation in coupled enzyme systems. For creatine kinase activity determination in the presence of CrP, the reaction sequence typically involves:

  • Creatine kinase catalyzing CrP + ADP → Creatine + ATP
  • Pyruvate kinase converting phosphoenolpyruvate + ADP → Pyruvate + ATP
  • Lactate dehydrogenase reducing pyruvate + NADH → Lactate + NAD⁺

The decrease in NADH absorbance at 340 nm is proportional to creatine kinase activity and, indirectly, to CrP concentration 14. While less sensitive than bioluminescence methods, spectrophotometric assays provide robust quantification suitable for quality control applications.

Chromatographic Separation Techniques

High-performance liquid chromatography (HPLC) and ion-exchange chromatography can separate creatine phosphate from creatine, ATP, ADP, and other phosphorylated metabolites. However, the acid-sensitivity of CrP necessitates careful pH control throughout the analytical procedure 1. Anion-exchange chromatography with alkaline mobile phases (pH 8.0–9.0) and UV detection at 210–214 nm enables simultaneous quantification of multiple energy metabolites in tissue extracts.

Therapeutic Applications Of Creatine Phosphate In Cardiovascular Medicine

Creatine phosphate has demonstrated significant therapeutic potential in cardiovascular disorders characterized by energy metabolism dysfunction, particularly in conditions involving ischemia and impaired ATP regeneration.

Treatment Of Atherosclerotic Plaques

A novel therapeutic approach combines exogenous creatine phosphate with creatine phosphokinase for treatment of atherosclerotic plaques 6. The rationale is based on observations that atherosclerotic tissue exhibits marked ischemia, hypoxia, and reduced enzymatic activity, resulting in severely depleted ATP and CrP levels within plaques 6.

Mechanistic Basis:

  • Ischemic and hypoxic conditions in atherosclerotic plaques lead to dramatic decreases in ATP, CrP, and enzyme activity 6
  • Exogenous CrP and CPK administration provides the energy substrate necessary to reactivate plaque enzymes and initiate biochemical processes 6
  • Increased ATP availability enables conversion to cyclic AMP (cAMP) via adenylyl cyclase, triggering enzyme cascades that may promote plaque stabilization or regression 6
  • The chemical stability advantage of CrP over ATP (which is rapidly hydrolyzed by extracellular ATPases and exerts negative inotropic effects at high concentrations) makes it the preferred high-energy phosphate for this application 6

Clinical protocols typically involve intravenous administration of CrP (1–2 g per dose) in combination with CPK enzyme, though optimal dosing regimens and treatment duration remain subjects of ongoing investigation 6.

Myocardial Protection During Ischemia-Reperfusion

Creatine phosphate administration has been explored for myocardial protection during cardiac surgery, percutaneous coronary intervention, and acute myocardial infarction. The compound's ability to rapidly regenerate ATP in energy-depleted cardiomyocytes may limit infarct size and preserve ventricular function 2,4.

Membrane-permeable CrP prodrugs offer particular promise in this context, as they can be administered orally or intravenously and achieve intracellular concentrations sufficient to support ATP regeneration during critical ischemic periods 2,4. Preclinical studies have demonstrated reduced markers of myocardial injury and improved hemodynamic parameters following CrP prodrug administration in animal models of coronary occlusion 2,4.

Neuroprotective Applications And Treatment Of Neurodegenerative Disorders

The central nervous system exhibits high and fluctuating energy demands, making neurons particularly vulnerable to ATP depletion. Creatine phosphate and related compounds have shown remarkable neuroprotective effects across multiple experimental models of neurological disease.

Mechanisms Of Neuroprotection

Creatine compounds, including creatine phosphate, cyclocreatine, and β-guanidinopropionic acid, mediate neuroprotection through several interconnected mechanisms 11,18:

  • Energy Buffer Maintenance: CrP serves as a spatial and temporal energy buffer, maintaining ATP/ADP ratios during periods of increased neuronal activity or metabolic stress 11,12,15
  • Mitochondrial Stabilization: Preservation of mitochondrial membrane potential and inhibition of cytochrome c release, thereby preventing activation of caspase-mediated apoptotic cascades 10,11
  • Calcium Homeostasis: Maintenance of ATP-dependent calcium pumps, preventing excitotoxic calcium overload 11
  • Oxidative Stress Reduction: Improved energy status reduces electron leak from the mitochondrial respiratory chain, decreasing reactive oxygen species generation 11

Clinical Applications In Specific Neurological Disorders

Amyotrophic Lateral Sclerosis (ALS): Creatine and creatine phosphate analogs have demonstrated efficacy in experimental ALS models, potentially slowing motor neuron degeneration through energy metabolism support 11,18.

Huntington's Disease: Oral creatine administration increases brain creatine and phosphocreatine levels, improving motor function and extending survival in transgenic mouse models 10,11.

Parkinson's Disease: Creatine supplementation may protect dopaminergic neurons from oxidative damage and energy depletion, though clinical trial results have been mixed 10,11.

Traumatic Brain Injury: Acute creatine phosphate administration following experimental brain trauma reduces lesion volume and improves functional outcomes, likely through preservation of cellular energy status during the critical post-injury period 10,11.

Stroke And Cerebral Ischemia: CrP prodrugs capable of crossing the blood-brain barrier show promise for acute neuroprotection during ischemic stroke, maintaining neuronal ATP levels and reducing infarct expansion 2,11.

Transmissible Spongiform Encephalopathies: Emerging evidence suggests creatine compounds may offer protective effects against prion-mediated neurodegeneration, potentially through maintenance of cellular energy homeostasis and inhibition of prion protein misfolding cascades 18.

Typical dosing for neuroprotective applications ranges from 5–20

OrgApplication ScenariosProduct/ProjectTechnical Outcomes
XENOPORT INC.Treatment of ischemia, heart failure, and neurodegenerative disorders requiring intracellular ATP regeneration and energy metabolism support.Membrane Permeable Creatine Phosphate ProdrugsEnhanced cellular uptake through membrane-permeable prodrug design that releases active creatine phosphate intracellularly, overcoming the poor membrane permeability of charged phosphate moiety.
BOEHRINGER MANNHEIM GMBHLarge-scale pharmaceutical production and research applications requiring high-purity creatine phosphate with simplified purification through thermal enzyme denaturation.Enzymatic Creatine Phosphate Synthesis ProcessAchieves near-quantitative conversion using creatine phosphokinase with 3-phosphoglyceric acid as phosphate donor; withstands heating at 80-90°C for enzyme inactivation without creatine phosphate degradation in alkaline conditions (pH 7.5-8.5).
Northwestern UniversityBiotechnology applications requiring cell-free protein production systems with optimized energy metabolism and extended reaction duration.Cell-Free Protein Synthesis (CFPS) SystemUtilizes creatine phosphate as secondary energy source for ATP regeneration, maintaining Energy Charge at 0.80-1.0 levels; enables sustained protein synthesis through substrate replenishment and phosphate management.
ARTCELL INVEST LTD.Treatment of atherosclerotic plaques characterized by severe ischemia, hypoxia, and depleted energy metabolism requiring biochemical reactivation.Creatine Phosphate-CPK Combination TherapyProvides exogenous high-energy phosphate and enzyme to reactivate depleted ATP and cAMP levels in ischemic atherosclerotic plaques; chemically more stable than ATP and avoids negative inotropic effects at high concentrations.
APLODAN FORMULATIONS LTD.Sports nutrition and muscle performance enhancement applications requiring sustained energy delivery and acid buffering during high-intensity intermittent exercise.Creatinol-O-Phosphate Timed-Release FormulationDelivers 0.5-5g creatinol-phosphate (preferably 1.5g twice daily) via controlled-release system; enhances ATP synthesis and acts as hydrogen ion buffer during intense muscular exercise, increasing endurance before fatigue onset.
Reference
  • Process for the preparation of creatine phosphate
    PatentInactiveUS3639211A
    View detail
  • Creatine phosphate prodrugs, compositions and uses thereof
    PatentWO2007146085A2
    View detail
  • Creatine phosphate analog prodrugs, compositions and uses thereof
    PatentInactiveUS8202852B2
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png